Update on Psychedelics Sector: Review of First Half of 2025

Update on Psychedelics Sector: Review of First Half of 2025

Expansion of Psychedelic Drugs Market in 2025

The psychedelic drugs market is experiencing rapid growth in 2025, driven by promising clinical trial results, increasing state-level regulatory acceptance, and growing interest from investors and regulators.

Key players in this space, such as Cybin and Compass Pathways, are making significant strides in their clinical programs. Cybin has reported significant progress and boasts a strong financial position with C$135 million in cash. On the other hand, Compass Pathways has announced positive Phase 3 results for its psilocybin therapy COMP360, showing statistically significant and clinically meaningful reductions in depression symptoms in treatment-resistant depression.

However, the regulatory landscape in the US remains fragmented. Psychedelics such as MDMA and psilocybin are still federally Schedule I substances, indicating no accepted medical use under federal law. Nevertheless, significant momentum exists towards reform. For instance, Texas passed Senate Bill 2308 to allocate $100 million in state funds for ibogaine clinical trials targeting opioid use disorder and mental health conditions.

At the federal level, Health Secretary Robert F. Kennedy Jr. and FDA head Marty Makary have emphasized psychedelic therapeutics as a top priority. Initiatives to speed drug approval processes could reduce review times substantially and relax traditional trial requirements like placebo controls, which have complicated psychedelic research.

Internationally, Australia has led the way, allowing psychiatrists to prescribe MDMA for PTSD and psilocybin for treatment-resistant depression in 2023.

The report finds that pilot programs offer a controlled environment for access and data collection, with a 50 percent success rate in implementing legislation necessary to operationalize enacted policies. Notably, New Mexico stands out as the sole state to successfully enact a licensed and regulated psilocybin therapy program through SB 219.

Clinical trials have been gaining traction, particularly when state-funded and focused on vulnerable populations like veterans and first responders. Indiana, for example, has established a therapeutic psilocybin research fund that compares psilocybin against existing treatments and ensures transparent fund administration and research application processing.

Corporate influence is also playing a role in the market. The report points to corporate entities' strategic efforts to gain commercial advantage through state trigger laws and compound-specific legislation favoring patented compounds like COMP360.

Despite these advancements, Cybin faces sector-related headwinds and regulatory hurdles that temper investor enthusiasm, leading analysts to suggest a cautious stance on its stock.

The market for psychedelic drugs is forecasted to be worth around $6.4 billion by 2025, with North America expected to account for approximately 45 to 50 percent of this market. As regulatory hurdles are overcome and public health and safety concerns are addressed, the psychedelic drugs market is poised for continued growth.

1. The growing interest from investors and regulators in the psychedelic drugs market is reflected in Cybin's financial position, with C$135 million in cash.
2. Compass Pathways has reported positive results from its psilocybin therapy, showing significant reductions in depression symptoms.
3. The regulatory landscape in the US is fragmented, with psychedelics like MDMA and psilocybin still classified as Schedule I substances.
4. Texas has allocated $100 million in state funds for ibogaine clinical trials targeting opioid use disorder and mental health conditions.
5. Health Secretary Robert F. Kennedy Jr. and FDA head Marty Makary have emphasized psychedelic therapeutics as a top priority.
6. International progress includes Australia allowing psychiatrists to prescribe MDMA for PTSD and psilocybin for treatment-resistant depression.
7. New Mexico is the only state to successfully enact a licensed and regulated psilocybin therapy program, demonstrating the potential for pilot programs.
8. Clinical trials, particularly those funded by states and focused on vulnerable populations, are gaining traction, with Indiana establishing a therapeutic psilocybin research fund.

Read also: